Journal article icon

Journal article

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)

Abstract:

Background The main toxicity of irinotecan in advanced colorectal cancer (CRC) is delayed diarrhoea. Intestinal SN-38, released by deconjugation of the parent glucuronide excreted into the bile or produced in situ by intestinal carboxylesterase, is toxic to the intestinal epithelium. The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin. We tested whether irinotecan and ciclosporin was non-inferior for anti-canc...

Expand abstract

Actions


Access Document


Publisher copy:
10.1016/j.ejca.2013.06.017

Authors


Middleton, G More by this author
Maughan, T More by this author
Gwyther, S More by this author
Expand authors...
Journal:
European Journal of Cancer
Volume:
49
Issue:
16
Pages:
3507-3516
Publication date:
2013-11-05
DOI:
EISSN:
1879-0852
ISSN:
0959-8049
URN:
uuid:2280cb92-06ca-475f-a5b5-0ebd68d09715
Source identifiers:
435537
Local pid:
pubs:435537
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP